Lancet publishes NanoFlu vaccine Phase 3 trial results
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Subscribe To Our Newsletter & Stay Updated